{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:33:23Z","timestamp":1747164803242,"version":"3.40.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jhep.2020.05.009","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T07:41:39Z","timestamp":1590824499000},"page":"12-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effective medical treatments for PSC needed ASAP - is AESOP the answer?"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6425","authenticated-orcid":false,"given":"Michael","family":"Trauner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2020.05.009_bib1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2020.05.009_bib2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"10.1016\/j.jhep.2020.05.009_bib3","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2020.05.009_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2020.05.009_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000440827","article-title":"Therapy of primary sclerosing cholangitis\u2013today and tomorrow","volume":"33","author":"Halilbasic","year":"2015","journal-title":"Dig Dis"},{"issue":"7","key":"10.1016\/j.jhep.2020.05.009_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.05.009_bib7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and challenges of selective Farnesoid X Receptor modulation","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.05.009_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","article-title":"Nonsteroidal FXR ligands: current status and clinical applications","volume":"256","author":"Gege","year":"2019","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.009_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.jhep.2020.05.009_bib10","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2020.05.009_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.009_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2020.05.009_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2020.05.009_bib14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group","volume":"336","author":"Lindor","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jhep.2020.05.009_bib15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.009_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12072-016-9769-7","article-title":"Prolonged fibroblast growth factor 19 response in patients with primary sclerosingcholangitis after an oral chenodeoxycholic acid challenge","volume":"11","author":"Zweers","year":"2017","journal-title":"Hepatol Int"},{"issue":"4 Pt B","key":"10.1016\/j.jhep.2020.05.009_bib17","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbadis.2017.08.016","article-title":"Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression","volume":"1864","author":"Erice","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jhep.2020.05.009_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in non-cirrhotic patients with nonalcoholic steatohepatitis: a phase 2 randomized controlled trial","author":"Patel","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2020.05.009_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2020.05.009_bib20","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1053\/j.gastro.2018.08.022","article-title":"FXR-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid","volume":"155","author":"Friedman","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820303019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820303019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T19:19:02Z","timestamp":1716664742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820303019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0168827820303019"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.05.009","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effective medical treatments for PSC needed ASAP - is AESOP the answer?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.02.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}